Safety and efficacy of sorafenib in elderly patients (pts) =65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. J Clin Oncol. 2008 May 20; 26(15_suppl):5045.